Curis Inc. is a Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas.
Curis Inc. (CRIS) had a rough trading day for Thursday March 04 as shares tumbled 5.97%, or a loss of $-0.58 per share, to close at $9.13. After opening the day at $9.64, shares of Curis Inc. traded as high as $9.99 and as low as $8.64. Volume was 2.38 million shares over 14,234 trades, against an average daily volume of n/a shares and a total float of 88.32 million.
As a result of the decline, Curis Inc. now has a market cap of $806.34 million. In the last year, shares of Curis Inc. have traded between a range of $13.44 and $0.63, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.
Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.
Curis Inc. is based out of Lexington, MA and has some 28 employees. Its CEO is James E. Dentzer.